The estimated Net Worth of Kyle Gano is at least 29.6 百万$ dollars as of 13 February 2024. Kyle Gano owns over 1,352 units of Neurocrine Biosciences stock worth over 16,418,614$ and over the last 11 years he sold NBIX stock worth over 8,572,681$. In addition, he makes 4,568,240$ as Chief Business Development and Strategy Officer at Neurocrine Biosciences.
Kyle has made over 45 trades of the Neurocrine Biosciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 1,352 units of NBIX stock worth 179,667$ on 13 February 2024.
The largest trade he's ever made was exercising 75,000 units of Neurocrine Biosciences stock on 2 January 2024 worth over 1,469,250$. On average, Kyle trades about 9,004 units every 76 days since 2013. As of 13 February 2024 he still owns at least 135,166 units of Neurocrine Biosciences stock.
You can see the complete history of Kyle Gano stock trades at the bottom of the page.
Dr. Kyle W. Gano Ph.D. serves as Chief Business Development and Strategy Officer of the Company. Dr. Gano was appointed Chief Business Development Officer in 2011, and Chief Business Development and Strategy Officer in 2020, and is responsible for all business and corporate development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma, BIAL, Jnana Therapeutics ,Voyager Therapeutics, Xenon Pharmaceuticals and Idorsia Pharmaceuticals Ltd. From 2001 to 2011, Dr. Gano held several positions of increasing responsibility at Neurocrine Biosciences spanning marketing analytics to business development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A in Finance from the University of California, Los Angeles.
As the Chief Business Development and Strategy Officer of Neurocrine Biosciences, the total compensation of Kyle Gano at Neurocrine Biosciences is 4,568,240$. There are 5 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of 9,450,830$.
Kyle Gano is 47, he's been the Chief Business Development and Strategy Officer of Neurocrine Biosciences since 2020. There are 20 older and 4 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
Kyle's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 21 years, insiders at Neurocrine Biosciences have traded over 159,913,426$ worth of Neurocrine Biosciences stock and bought 103,400 units worth 589,660$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of 1,567,813$. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth 2,090,333$.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: